SCHEMBL3660693

SCHEMBL3660693

CN1C(=O)Cc2cc(C(N)=O)ccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 3/20 0.59
SIRT2 Q8IXJ6 1/20 0.53
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 2/20 0.50
HSD17B10 Q99714 2/20 0.50
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
GAA P10253 2/20 0.47
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
BRD4 O60885 1/20 0.45
BRPF1 P55201 1/20 0.45
TRIM24 O15164 1/20 0.45
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.43
BMPR1B O00238 1/20 0.42
BMPR1A P36894 1/20 0.42
ACVRL1 P37023 1/20 0.42
ACVR1 Q04771 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29913739 1.00 SMYD3 (0.59) SMYD3SIRT2ALDH1A1KDM4EHSD17B10
SCHEMBL27801761 0.87 KDM4E (0.47) SMYD3SIRT2ALDH1A1KDM4EHSD17B10
SCHEMBL1965892 0.85 SMYD3 (0.60) SMYD3ALDH1A1HSD17B10HDAC1HDAC2
SCHEMBL31348187 0.85 SMYD3 (0.60) SMYD3ALDH1A1HSD17B10HDAC1HDAC2
SCHEMBL19357202 0.85 MAPT (0.60) SMYD3ALDH1A1HDAC1HDAC2GAA
SCHEMBL30364090 0.82 ALDH1A1 (0.44) SMYD3SIRT2ALDH1A1KDM4EHSD17B10
SCHEMBL19691218 0.82 ALDH1A1 (0.44) SMYD3SIRT2ALDH1A1KDM4EHSD17B10
Hydrochloric Acid SCHEMBL10855737 0.82 SMYD3 (0.54) SMYD3ALDH1A1HDAC1HDAC2GAA
SCHEMBL24233407 0.81 SMN1; SMN2 (0.60) SMYD3ALDH1A1KDM4EHSD17B10HDAC1
SCHEMBL30364145 0.81 ALDH1A1 (0.43) SMYD3SIRT2ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230101819-A1 SMYD Inhibitors EPIZYME INC (US) 2023-03-30 US disclosed
CN-101970426-A Indazolyl-, benzimidazolyl-, benzotriazolyl-substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIV HEALTH NETWORK 2011-02-09 CN disclosed
EP-2235004-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER University Health Network (CA) 2010-10-06 EP disclosed
WO-2009079767-A9 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-10-01 WO disclosed
WO-2009079767-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230101819-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 SMYD3 1/4885SIRT2 2152/4885ALDH1A1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.